A Phase II Study of Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-002532-28

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to determine the Hematologic Improvement (HI) rate during the 12-month study period with rATG (Thymoglobulin), as defined by the IWG and published in 2006 by Cheson and colleagues


Critère d'inclusion

  • Low And Intermediate-1 Risk Myelodysplastic Syndrome in adult patients 60 years or younger